WO2002026718A3 - Inhibiteurs du facteur xa à base de pyrimidine-4-one bicyclique - Google Patents

Inhibiteurs du facteur xa à base de pyrimidine-4-one bicyclique Download PDF

Info

Publication number
WO2002026718A3
WO2002026718A3 PCT/US2001/030335 US0130335W WO0226718A3 WO 2002026718 A3 WO2002026718 A3 WO 2002026718A3 US 0130335 W US0130335 W US 0130335W WO 0226718 A3 WO0226718 A3 WO 0226718A3
Authority
WO
WIPO (PCT)
Prior art keywords
factor
compounds
based inhibitors
bicyclic pyrimidin
pyrimidin
Prior art date
Application number
PCT/US2001/030335
Other languages
English (en)
Other versions
WO2002026718A2 (fr
Inventor
Penglie Zhang
Wenhao Li
Wenrong Huang
Lingyan Wang
Zhaozhong Jon Jia
Robert M Scarborough
Bing-Yan Zhu
Original Assignee
Millennium Pharm Inc
Penglie Zhang
Wenhao Li
Wenrong Huang
Lingyan Wang
Zhaozhong Jon Jia
Robert M Scarborough
Bing-Yan Zhu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc, Penglie Zhang, Wenhao Li, Wenrong Huang, Lingyan Wang, Zhaozhong Jon Jia, Robert M Scarborough, Bing-Yan Zhu filed Critical Millennium Pharm Inc
Priority to AU2002214546A priority Critical patent/AU2002214546A1/en
Publication of WO2002026718A2 publication Critical patent/WO2002026718A2/fr
Publication of WO2002026718A3 publication Critical patent/WO2002026718A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Cette invention a trait à de nouveaux composés contenant une nouvelle pyrimidine-4-one bicyclique, correspondant à la formule (I) ou à la formule (II), ainsi qu'à leurs isomères, leurs sels, leurs hydrates, solvates ou promédicaments, acceptables du point de vue pharmaceutique, lesquelles substances font montre d'une action à l'encontre du facteur mammalien Xa. Elle concerne également des compositions renfermant ces composés. Ces derniers ainsi que les compositions selon l'invention se révèlent des plus utiles, in vitro comme in vivo, pour prévenir ou traiter chez des mammifères des états pathologiques se caractérisant par une thrombose indésirable.
PCT/US2001/030335 2000-09-29 2001-10-01 Inhibiteurs du facteur xa à base de pyrimidine-4-one bicyclique WO2002026718A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002214546A AU2002214546A1 (en) 2000-09-29 2001-10-01 Bicyclic pyrimidin-4-one based inhibitors of factor xa

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23633100P 2000-09-29 2000-09-29
US60/236,331 2000-09-29

Publications (2)

Publication Number Publication Date
WO2002026718A2 WO2002026718A2 (fr) 2002-04-04
WO2002026718A3 true WO2002026718A3 (fr) 2002-08-29

Family

ID=22889064

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/030335 WO2002026718A2 (fr) 2000-09-29 2001-10-01 Inhibiteurs du facteur xa à base de pyrimidine-4-one bicyclique

Country Status (2)

Country Link
AU (1) AU2002214546A1 (fr)
WO (1) WO2002026718A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002317377A1 (en) * 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
EP1553947A4 (fr) * 2002-10-21 2006-11-29 Bristol Myers Squibb Co Quinazolinones et derives de celles-ci comme inhibiteurs du facteur xa
AR051596A1 (es) * 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
JP2008543968A (ja) * 2005-06-28 2008-12-04 オーキッド リサーチ ラボラトリーズ リミテッド 新規なピラゾロピリミジノン誘導体
US8003656B2 (en) 2006-08-23 2011-08-23 Neurogen Corporation 2-phenoxy pyrimidinone analogues
ES2542835T3 (es) * 2009-01-08 2015-08-12 Resverlogix Corporation Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
WO2016003917A1 (fr) * 2014-07-03 2016-01-07 Quanticel Pharmaceuticals, Inc. Inhibiteurs de la déméthylase-1 spécifique de la lysine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4276295A (en) * 1978-12-19 1981-06-30 Masayuki Ishikawa 3-Aromatic moiety substituted-4(3H)-quinazolinones, process for production thereof, and use thereof
WO1999054313A1 (fr) * 1998-04-17 1999-10-28 Boehringer Ingelheim Pharma Kg Bicyclenes a effet antithrombotique

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4276295A (en) * 1978-12-19 1981-06-30 Masayuki Ishikawa 3-Aromatic moiety substituted-4(3H)-quinazolinones, process for production thereof, and use thereof
WO1999054313A1 (fr) * 1998-04-17 1999-10-28 Boehringer Ingelheim Pharma Kg Bicyclenes a effet antithrombotique

Also Published As

Publication number Publication date
WO2002026718A2 (fr) 2002-04-04
AU2002214546A1 (en) 2002-04-08

Similar Documents

Publication Publication Date Title
WO2001056989A3 (fr) Inhibiteurs du facteur xa contenant du phenylene bivalent
WO2001064643A3 (fr) Benzamides et inhibiteurs associes du facteur xa
WO2002026712A3 (fr) Amines quaternaires et inhibiteurs du facteur xa associes
WO2001072708A3 (fr) INHIBITEURS D'OXINIDOLE DU FACTEUR Xa
WO2001057021A3 (fr) 2-[1H]-QUINOLONE ET 2-[1H]-QUINOXALONE INHIBITEURS DU FACTEUR Xa
WO2000071493A3 (fr) INHIBITEURS DU FACTEUR Xa
WO2001019829A3 (fr) Pyrazolopyrimidines en tant qu'agents therapeutiques
IL183340A0 (en) [1,2,4] triazolo[4,3-a] pyridine derivatives and pharmaceutical compositions containing them
MY124390A (en) Substituted bicyclic derivatives useful as anticancer agents
AU5879299A (en) Adenine derivatives
WO2002026720A3 (fr) INHIBITEURS DE FACTOR Xa A BASE DE PIPERAZINE
HK1089163A1 (en) Quinoxaline derivatives as neutrophil elastase inhibitors and their use
DK1029853T3 (da) Heteroaromatiske bicykliske derivativer, der er egnede som anticancermidler
CA2290766A1 (fr) Methode de traitement de la tolerance due au nitrate
WO2001098277A3 (fr) Derives bicycliques substitues destines au traitement de la croissance cellulaire anormale
HK1068136A1 (en) Muscarinic antagonists
CA2414018A1 (fr) Derives de 2-aminocarbonyl-9h-purine
MXPA03006483A (es) Derivados de fenilo.
WO2000071515A3 (fr) INHIBITEURS DU FACTEUR Xa
WO2000047554A3 (fr) INHIBITEURS DU FACTEUR Xa
WO2000055124A3 (fr) Composes et compositions utilises comme inhibiteurs de protease
AU2002213421A1 (en) Condensed pyridoindole derivatives
NO20022124L (no) Imidazopyridinderivater som fosfodiesterase VII-inhibitorer
WO2002026718A3 (fr) Inhibiteurs du facteur xa à base de pyrimidine-4-one bicyclique
MX9709910A (es) Compuestos que contienen arginina e imitaciones de arginina, su uso y composiciones que los contienen.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP